GLP-1 Medications and Muscle Loss: What the Research Says and How to Fight Back

Here is a number worth sitting with: in clinical trials, GLP-1 receptor agonists produce total body weight reductions of 5% to 18%, with some incretin-based therapies pushing that figure closer to 25%. Those are genuinely impressive results for a chronic disease that has resisted effective treatment for decades. But buried inside those headline numbers is a detail that deserves far more attention than it typically gets — a meaningful portion of that weight is not fat. It is muscle.

Research published in Metabolism: Clinical and Experimental found that over 25% of total weight lost during incretin receptor agonist therapy typically comes from fat-free mass, which includes skeletal muscle. A separate review in Current Opinion in Clinical Nutrition and Metabolic Care put the figure even higher, noting that up to 40% of total weight loss can come from fat-free mass during GLP-1 therapy. For younger, otherwise healthy men with significant fat stores to burn, this may be manageable. For older men, men with limited muscle reserves, or anyone already on the edge of what researchers call sarcopenic obesity — a dangerous convergence of excess fat and insufficient muscle — these numbers carry real clinical weight.

This is not an argument against GLP-1 medications. The cardiometabolic benefits are well-documented, and for many men these drugs are genuinely life-changing. But the muscle loss question is one that patients are rarely counseled on adequately before they start, and the gap between what the research recommends and what happens in real clinical practice is significant. Understanding the mechanism behind this muscle loss — and the specific, evidence-based strategies that can counter it — may be the most important thing a man on GLP-1 therapy can do to protect his long-term health.

Why GLP-1 Therapy Puts Muscle at Risk

The mechanism is not mysterious. GLP-1 receptor agonists work primarily by suppressing appetite and slowing gastric emptying, which creates a sustained caloric deficit. That deficit drives weight loss — but the human body under significant caloric restriction does not selectively burn fat. It draws from lean tissue as well, especially when protein intake falls below what muscle maintenance requires and when resistance-based exercise is absent from the picture.

A 2026 narrative review in Acta Diabetologica synthesized the current evidence on muscle loss during GLP-1 therapy and identified a convergence of factors that make metabolically compromised individuals particularly vulnerable. Chronic low-grade inflammation, mitochondrial dysfunction, and altered protein metabolism — all hallmarks of obesity and type 2 diabetes — already prime the body for muscle degradation. Layer a significant pharmacologically induced caloric deficit on top of that pre-existing vulnerability, and you have the conditions for accelerated sarcopenia.

What makes this especially consequential is the downstream effect on metabolic health. Skeletal muscle is the primary site of glucose disposal in the body. Losing it does not just affect strength or appearance — it directly worsens insulin resistance, which is precisely the condition GLP-1 medications are often prescribed to treat. The review in Acta Diabetologica noted that loss of muscle mass and strength impairs mobility and quality of life while simultaneously accelerating cardiometabolic decline and increasing mortality risk. You cannot achieve the full metabolic benefit of weight loss if a quarter or more of what you are losing is the tissue most responsible for metabolic regulation.

A 2025 review in Pharmacological Research added important mechanistic context, noting that GLP-1 receptor agonists may contribute to unintended reductions in skeletal muscle mass through pathways that go beyond simple caloric restriction — potentially exacerbating sarcopenic obesity particularly in older or frail individuals with limited muscular reserves. The practical implication is clear: muscle preservation cannot be left to chance during GLP-1 therapy. It requires active, deliberate intervention.

The Evidence-Based Strategy to Preserve Muscle

The most important intervention, and the one with the strongest evidence base, is resistance training. Not cardio. Not walking. Resistance training — progressive, structured, load-bearing exercise that creates mechanical tension in skeletal muscle and signals the body to maintain and rebuild lean tissue even in a caloric deficit. The 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society was unambiguous on this point, recommending resistance training as a core pillar of muscle and bone mass preservation during GLP-1 therapy. This means compound movements — squats, deadlifts, rows, presses — performed at least two to three times per week with progressive overload over time. It is not optional. It is the single most effective tool available for counteracting therapy-induced muscle loss.

Protein intake is the other non-negotiable. GLP-1 medications suppress appetite indiscriminately, which means men on these drugs frequently under-eat protein alongside everything else. Given that muscle protein synthesis requires adequate leucine availability and overall amino acid flux, falling short on protein while in a significant caloric deficit is a reliable path to muscle loss. The expert panel that produced the 2025 joint advisory specifically flagged this risk, emphasizing that optimal protein intake during GLP-1 therapy must be deliberately planned, not assumed. Most men aiming to preserve muscle during active weight loss will benefit from targeting 1.6 to 2.2 grams of protein per kilogram of body weight daily — potentially toward the higher end if they are older or have lower baseline muscle mass. High-quality sources like eggs, lean meats, Greek yogurt, cottage cheese, and protein supplements should anchor every meal, even when total food volume is dramatically reduced.

Beyond those two primary pillars, the research identifies several targeted nutritional strategies worth considering when protein and training are already in place but additional support is needed. The review in Current Opinion in Clinical Nutrition and Metabolic Care highlighted the potential role of specific nutrients including branched-chain amino acids, creatine, leucine supplementation, omega-3 fatty acids, and vitamin D in supporting muscle health during pharmacological weight loss. Of these, creatine monohydrate has arguably the strongest general evidence base for supporting muscle performance and lean mass retention during caloric restriction, and omega-3 fatty acids have demonstrated anti-inflammatory and anti-catabolic properties relevant to the metabolic context of GLP-1 use.

Looking further ahead, emerging pharmacological approaches including bimagrumab, trevogrumab, and garetosmab — agents that inhibit activin and myostatin signaling, thereby blunting muscle breakdown while promoting fat loss — have shown early promise in clinical trials, either alone or in combination with incretin receptor agonists. These are not yet widely available, but they represent a meaningful step toward a future where obesity pharmacotherapy can be genuinely muscle-sparing rather than muscle-neutral at best.

What This Means For You

If you are on a GLP-1 medication and no one has talked to you about muscle loss, that is a failure of clinical communication — not a sign that the problem does not exist. The research is consistent and the stakes are real. Significant weight loss without a deliberate muscle preservation strategy produces a body that weighs less but functions worse metabolically, structurally, and functionally over time.

The solution is not complicated, but it is non-negotiable. Lift weights consistently. Hit your protein targets every single day regardless of how suppressed your appetite is. Consider targeted supplementation when your baseline is solid. Talk to your prescribing clinician about body composition monitoring — not just scale weight — so you can actually track what you are losing and what you are keeping. GLP-1 medications can be a powerful tool in the right hands. But the hands doing the most important work are still yours, in the gym and at the dinner table.